Following the successful IPO of Shoulder Innovations, Executive Chairman and CEO, Rob Ball, was featured on NYSE TV to discuss the company’s journey, innovations, product advantages, and future direction.
In the interview, Rob dives into the driving force behind Shoulder Innovations’ focused approach to shoulder arthroplasty. From the proprietary InSet™ glenoid technology to preoperative planning, and efficient surgical instrumentation, Rob explains how SI is uniquely poised to continue gaining market share in one of the fastest-growing areas in orthopedics.
He also shares insights on:
- Why shoulder replacements are the company’s primary focus
- How SI is uniquely addressing implant longevity and patient outcomes
- The growing shift toward outpatient procedures
- SI’s commitment to reducing surgical complexity and cost
This appearance follows our exciting public debut on the New York Stock Exchange under the ticker SI, marked by ringing the Closing Bell, a symbolic moment for the SI team, surgeon partners, and the patients we serve.
Watch the full interview below to hear more from Rob Ball on what’s ahead for Shoulder Innovations: